Targeted delivery of proven chemotherapeutic agents via heat-sensitive liposomes
“Leaky” tumor blood vessels promote access of liposomes
Heat application further increases liposomal penetration
Heat-sensitive liposomes selectively release chemotherapeutic agent
LTSL technology is agnostic regarding the means of heating. Whether combined with radiofrequency thermal ablation (RFA) to expand the “treatment zone” for solid tumors, microwave ablation for superficial tumors, or high-intensity focused ultrasound for difficult to reach tumors, LTSL has shown its mechanism to be effective.
While ThermoDox®, liposomal encapsulation of doxorubicin, is our first investigational product developed through application of LTSL technology, the LTSL platform has shown its applicability to a variety of drug products including formulations of docetaxel and carboplatin. Celsion licensed the exclusive worldwide rights to the LTSL technology from Duke University.